Kemp Dolliver
Stock Analyst at Brookline Capital
(0.28)
# 4,158
Out of 4,876 analysts
17
Total ratings
25%
Success rate
-28.82%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $17 | $4.70 | +261.70% | 1 | Dec 5, 2024 | |
| EYEN Eyenovia | Downgrades: Hold | n/a | $10.88 | - | 2 | Nov 15, 2024 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $0.52 | - | 2 | Oct 2, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $0.76 | +376.82% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $2.37 | +1,422.20% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $1.60 | +1,862.50% | 1 | Jan 25, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Downgrades: Hold | n/a | $0.33 | - | 1 | Dec 19, 2023 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $81.49 | +22.71% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $1.99 | +2,766.05% | 2 | Oct 12, 2023 | |
| GNLX Genelux | Initiates: Hold | $25 | $3.00 | +733.33% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $5.45 | +244.04% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.69 | +1,057.24% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $1.01 | +459.41% | 1 | Feb 2, 2022 |
Y-mAbs Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $17
Current: $4.70
Upside: +261.70%
Eyenovia
Nov 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $10.88
Upside: -
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.52
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $0.76
Upside: +376.82%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.37
Upside: +1,422.20%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $1.60
Upside: +1,862.50%
Cyclacel Pharmaceuticals
Dec 19, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.33
Upside: -
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $81.49
Upside: +22.71%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $1.99
Upside: +2,766.05%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $3.00
Upside: +733.33%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $5.45
Upside: +244.04%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.69
Upside: +1,057.24%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $1.01
Upside: +459.41%